| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
| Sponsors and Collaborators: |
Herbert Irving Comprehensive Cancer Center National Cancer Institute (NCI) |
| Information provided by: | National Cancer Institute (NCI) |
| ClinicalTrials.gov Identifier: | NCT00008216 |
Purpose
RATIONALE: Giving chemotherapy drugs and total-body irradiation before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets.
PURPOSE: This phase II trial is studying the effectiveness of donor peripheral blood stem cell transplant in treating patients with hematologic cancer.
| Condition | Intervention | Phase |
|
Langerhans Cell Histiocytosis Leukemia Lymphoma Multiple Myeloma and Plasma Cell Neoplasm Myelodysplastic Syndromes Myelodysplastic/Myeloproliferative Diseases |
Procedure: peripheral blood stem cell transplantation |
Phase II |
| Genetics Home Reference related topics: | aceruloplasminemia hemophilia |
| MedlinePlus related topics: | Cancer Hodgkin's Disease Leukemia, Adult Acute Leukemia, Adult Chronic Leukemia, Childhood Lymphoma Multiple Myeloma |
| Study Type: | Interventional |
| Study Design: | Treatment |
| Official Title: | The Use Of Peripheral Blood Stem Cells For Allogeneic Transplantation |
| Estimated Enrollment: | 62 |
| Study Start Date: | January 1997 |
OBJECTIVES:
OUTLINE: Patients receive a preparative chemoradiotherapeutic regimen and graft-versus-host disease prophylaxis prior to transplantation. Patients undergo allogeneic peripheral blood stem cell transplantation on day 0.
Patients are followed every 1-2 weeks for 6 months and at 9, 12, 24, and 36 months.
PROJECTED ACCRUAL: A total of 62 patients will be accrued for this study within 4 years.
Eligibility
| Ages Eligible for Study: | up to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Diagnosis of one of the following:
Chronic myelogenous leukemia
Acute myeloid leukemia, acute lymphocytic leukemia, lymphoma, histiocytoses, myelodysplasia, juvenile chronic myelomonocytic leukemia, aplastic anemia, paroxysmal nocturnal hemoglobinuria, or Fanconi's anemia
Hereditary immunodeficiency disorders
Sickle cell anemia or beta-thalassemia
Storage disorders (e.g., Gaucher's disease, Hurler's disease, or metachromatic leukodystrophy)
PATIENT CHARACTERISTICS:
Age:
Performance status:
Life expectancy:
Hematopoietic:
Hepatic:
Renal:
PRIOR CONCURRENT THERAPY:
Biologic therapy
Chemotherapy
Endocrine therapy
Radiotherapy
Surgery
Contacts and Locations| United States, New York | |||||
| Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center | Recruiting | ||||
| New York, New York, United States, 10032 | |||||
| Contact: Clinical Trials Office - Herbert Irving Comprehensive Cancer C 212-305-8615 | |||||
| Herbert Irving Comprehensive Cancer Center |
| National Cancer Institute (NCI) |
| Study Chair: | David G. Savage, MD | Herbert Irving Comprehensive Cancer Center |
More Information
Clinical trial summary from the National Cancer Institute's PDQ® database
|
| Study ID Numbers: | CDR0000068388, CPMC-IRB-AAAA5571, CPMC-CAMP-016, NCI-G00-1891 |
| First Received: | January 6, 2001 |
| Last Updated: | July 23, 2008 |
| ClinicalTrials.gov Identifier: | NCT00008216 |
| Health Authority: | Unspecified |
|
|
|
|
|
|
|
